These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27885314)

  • 41. Diaphragmatic surgery during cytoreduction for primary or recurrent epithelial ovarian cancer: a review of the literature.
    Papadia A; Morotti M
    Arch Gynecol Obstet; 2013 Apr; 287(4):733-41. PubMed ID: 23341061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
    Sood AK; Sorosky JI; Gelder MS; Buller RE; Anderson B; Wilkinson EJ; Benda JA; Morgan LS
    Cancer; 1998 May; 82(9):1731-7. PubMed ID: 9576296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of aggressive surgical cytoreduction in advanced ovarian cancer.
    Chang SJ; Bristow RE; Chi DS; Cliby WA
    J Gynecol Oncol; 2015 Oct; 26(4):336-42. PubMed ID: 26197773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytoreductive surgery in the management of ovarian cancer.
    Schwartz PE
    Oncology (Williston Park); 2008 Aug; 22(9):1025-33; discussion 1033-8, 1041, 1045. PubMed ID: 18777954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer.
    Salani R; Axtell A; Gerardi M; Holschneider C; Bristow RE
    Gynecol Oncol; 2008 Feb; 108(2):271-5. PubMed ID: 18164380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.
    Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
    Gynecol Oncol; 2008 Feb; 108(2):265-70. PubMed ID: 18055006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
    Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
    Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review.
    Vernooij F; Heintz P; Witteveen E; van der Graaf Y
    Gynecol Oncol; 2007 Jun; 105(3):801-12. PubMed ID: 17433422
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of comprehensive surgical treatment in patients with ovarian cancer.
    Goff BA; Matthews BJ; Larson EH; Andrilla CH; Wynn M; Lishner DM; Baldwin LM
    Cancer; 2007 May; 109(10):2031-42. PubMed ID: 17420977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction.
    Bristow RE; Eisenhauer EL; Santillan A; Chi DS
    Gynecol Oncol; 2007 Feb; 104(2):480-90. PubMed ID: 17166564
    [TBL] [Abstract][Full Text] [Related]  

  • 53. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary.
    Eisenkop SM; Spirtos NM; Lin WC
    Gynecol Oncol; 2006 Oct; 103(1):329-35. PubMed ID: 16876853
    [TBL] [Abstract][Full Text] [Related]  

  • 54. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
    Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals.
    Paulsen T; Kjaerheim K; Kaern J; Tretli S; Tropé C
    Int J Gynecol Cancer; 2006; 16 Suppl 1():11-7. PubMed ID: 16515561
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients.
    Earle CC; Schrag D; Neville BA; Yabroff KR; Topor M; Fahey A; Trimble EL; Bodurka DC; Bristow RE; Carney M; Warren JL
    J Natl Cancer Inst; 2006 Feb; 98(3):172-80. PubMed ID: 16449677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.
    Schrag D; Earle C; Xu F; Panageas KS; Yabroff KR; Bristow RE; Trimble EL; Warren JL
    J Natl Cancer Inst; 2006 Feb; 98(3):163-71. PubMed ID: 16449676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.
    Engelen MJ; Kos HE; Willemse PH; Aalders JG; de Vries EG; Schaapveld M; Otter R; van der Zee AG
    Cancer; 2006 Feb; 106(3):589-98. PubMed ID: 16369985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Sato E; Olson SH; Ahn J; Bundy B; Nishikawa H; Qian F; Jungbluth AA; Frosina D; Gnjatic S; Ambrosone C; Kepner J; Odunsi T; Ritter G; Lele S; Chen YT; Ohtani H; Old LJ; Odunsi K
    Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18538-43. PubMed ID: 16344461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients.
    Sharma S; Driscoll D; Odunsi K; Venkatadri A; Lele S
    Am J Obstet Gynecol; 2005 Dec; 193(6):2077-82. PubMed ID: 16325619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.